Eudaimonia Partners’s Immunogen Inc IMGN Stock Holding History

Eudaimonia Partners’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-277	Closed	-$2K	–	1447
2021 Q1	$2K	Buy	+277	New	+$2.26K	﹤0.01%	1509

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eudaimonia Partners's IMGN Position: Q2 2021 in Review

Eudaimonia Partners sold out of Immunogen Inc (IMGN) in Q2 2021, closing a stake of 277 shares — an estimated $2K sold.

Eudaimonia Partners first reported a position in IMGN in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 214 funds tracked by Wall St. Rank hold IMGN as of Q2 2021.

Eudaimonia Partners reported no remaining Immunogen Inc position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 277 Immunogen Inc shares in Q2 2021, an estimated $2K.
Eudaimonia Partners first reported a position in Immunogen Inc in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Immunogen Inc position peaked at $2K in Q1 2021.
214 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.